InNexus Biotechnology, Inc.
IXSBF
$0.00
$0.000.00%
OTC PK
| 03/31/2011 | 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.36% | -30.66% | -44.50% | -45.06% | -48.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.47% | -39.43% | -45.98% | -43.60% | -45.47% |
| Operating Income | 48.47% | 39.43% | 45.98% | 43.60% | 49.19% |
| Income Before Tax | 31.67% | 18.81% | 12.05% | 7.77% | 14.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.67% | 18.81% | 12.05% | 7.77% | 14.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.67% | 18.81% | 12.05% | 7.77% | 14.09% |
| EBIT | 48.47% | 39.43% | 45.98% | 43.60% | 49.19% |
| EBITDA | 54.19% | 41.23% | 49.00% | 47.15% | 52.56% |
| EPS Basic | 56.37% | 47.52% | 39.76% | 35.89% | 32.71% |
| Normalized Basic EPS | 59.91% | 49.70% | 40.67% | 30.65% | 28.73% |
| EPS Diluted | 56.37% | 47.52% | 39.76% | 35.89% | 32.71% |
| Normalized Diluted EPS | 59.91% | 49.70% | 40.67% | 30.65% | 28.73% |
| Average Basic Shares Outstanding | 60.63% | 54.97% | 41.90% | 26.02% | 20.85% |
| Average Diluted Shares Outstanding | 60.63% | 54.97% | 41.90% | 26.02% | 20.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |